Increased international business travel to moderate or high endemic areas of hepatitis A and B may leave many business travelers at risk for infection if not vaccinated. Many international business travelers depart for hepatitis A and B endemic areas within 2 months of the decision to travel. Many of these travelers do not seek pretravel medical advice and are unaware of the risks and modes of acquiring hepatitis A and B. Monovalent vaccines and a combined hepatitis A and B vaccine are available and can be administered on an accelerated schedule. Because many areas endemic for hepatitis A are also endemic for hepatitis B, accelerated administration of the combined vaccine can offer protection for many international business travelers destined for areas endemic for both diseases and should be part of corporate travel immunization programs.
From the Division of Gastroenterology and Hepatology (Dr Connor), New York Presbyterian Hospital-Cornell Medical Center, New York, N.Y.; The New York Center for Travel and Tropical Medicine (Dr Connor), New York, N.Y.; and Corporate Medical Solutions, LLC (Dr Patron), Spring, Tex.
Address correspondence to: Bradley A. Connor, MD, The New York Center for Travel and Tropical Medicine, 50 East 69th Street, New York, NY; E-mail: email@example.com.